A Phase 2a Randomized, Double-Blind, Multicenter, Placebo and Active Controlled Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy

Trial Profile

A Phase 2a Randomized, Double-Blind, Multicenter, Placebo and Active Controlled Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 May 2017

At a glance

  • Drugs ASP 3662 (Primary) ; Pregabalin
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 03 Jun 2016 Status changed from recruiting to discontinued.
    • 18 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 03 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top